Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Devonian Health GroupDVHGF 53 3-Year ROIIC % is -31.96 as of Jul. 2025. GuruFocus rates DVHGF with a GF Score™ of 53/100 and a GF Value™ of $2.23 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 1,322 Biotechnology companies, Devonian Health Group ranks worse than 60.89% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Devonian Health Group's 3-Year ROIIC % for the quarter that ended in Jul. 2025 was -31.96%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Devonian Health Group's 3-Year ROIIC % or its related term are showing as below:
DVHGF's 3-Year ROIIC % is ranked worse than 60.89% of 1322
companies
in the Biotechnology industry
Industry Median: -4.835
vs DVHGF: -31.96
Devonian Health Group (OTCPK:DVHGF) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Devonian Health Group 3-Year ROIIC % Related Terms
Devonian Health Group 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Devonian Health Group's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DVHGF vs VRTX, REGN, ALNY: 3-Year ROIIC % Comparison
For the Biotechnology subindustry, Devonian Health Group's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Devonian Health Group 3-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Devonian Health Group's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Devonian Health Group's 3-Year ROIIC % falls into.
Devonian Health Group's 3-Year ROIIC % for the quarter that ended in Jul. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -0.563 (Jul. 2025) - -2.252 (Jul. 2022) )
/
( 5.224 (Jul. 2025) - 10.71 (Jul. 2022) )
=
1.689
/
-5.486
=
-30.79%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Devonian Health Group (DVHGF) has a 3-Year ROIIC % of -31.96 as of Jul. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Devonian Health Group and its competitors. According to the industry distribution chart, Devonian Health Group ranks #805 out of 1322 companies in the Biotechnology industry, placing it in the top 60.9%.
Is Devonian Health Group's 3-Year ROIIC % too high?
Devonian Health Group's current 3-Year ROIIC % is -31.96. Based on the distribution chart, Devonian Health Group ranks #805 out of 1322 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Devonian Health Group has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Devonian Health Group's 3-Year ROIIC % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Devonian Health Group ranks #805 out of 1322 companies for 3-Year ROIIC %. This places Devonian Health Group in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Biotechnology company?
A good 3-Year ROIIC % depends on the Biotechnology industry context. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Devonian Health Group and its competitors. Devonian Health Group's current 3-Year ROIIC % is -31.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Devonian Health Group stock overvalued right now?
Based on GuruFocus' analysis, Devonian Health Group (DVHGF) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.23, compared to a current price of $7.00 — trading 213.9% above its estimated fair value. The current 3-Year ROIIC % is -31.96. Devonian Health Group's overall GF Score™ is 53/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Devonian Health Group (DVHGF), the current 3-Year ROIIC % is -31.96 as of Jul. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Devonian Health Group (DVHGF) Overvalued in 2026?
Based on GuruFocus' analysis, Devonian Health Group stock appears to be overvalued.
The current stock price of $7.00 is trading 213.9% above its estimated GF Value™ of $2.23.
GuruFocus considers Devonian Health Group to be Significantly Overvalued.
Key valuation signals for DVHGF:
3-Year ROIIC %: -31.96
GF Value™: $2.23 vs. price of $7.00 (213.9% above fair value)
No single metric tells the full story. See the DVHGF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Devonian Health Group Inc is operating in the pharmaceutical sector. It is engaged in the development and distribution of botanical drugs. The group is also involved in the development of value-added products for dermo-cosmetics. It has established a research effort focused on the anticipation of new solutions in the medical sector as well as in the cosmetic sector. The company's technology platform, The Supra Molecular Complex Extraction and Stabilization Technology provides a process of extraction, purification, stabilization, and conditioning of molecular complexes, as active botanical ingredients, from plants and algae. Its product portfolio includes pharmaceuticals like Thykamine, Pantoprazole, and Cleo-35; and cosmeceutical products like R-Spinasome and Purgenesis.
53GF Score
Get the complete analysis for DVHGF
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DVHGF has been successfully added to your 
